First human tests begin for promising zika shot
NCT ID NCT06334393
Summary
This early-stage trial tested a new Zika virus vaccine candidate in 150 healthy adults who had never been exposed to similar viruses. Researchers gave participants two shots, one month apart, to check for safety issues and see if the vaccine triggered an immune response against Zika. The study compared different vaccine doses and formulations to find the most promising combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ZIKA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Flourish Research
Chicago, Illinois, 60640, United States
-
Velocity Clinical Research
Sioux City, Iowa, 51106, United States
-
Velocity Clinical Research
Lincoln, Nebraska, 68510, United States
-
Velocity Clinical Research
Omaha, Nebraska, 68134, United States
Conditions
Explore the condition pages connected to this study.